MCP Waters-The Science of What's Possible
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on August 1, 2007.
This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
T600063-MCP200v1
6/8/1437    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Glossary
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kita, Y.
Right arrow Articles by Nishimura, S.-I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kita, Y.
Right arrow Articles by Nishimura, S.-I.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on November 15, 2006
Revised on May 18, 2007
Accepted on May 23, 2007

Quantitative glycomics of human whole serum glycoproteins based on the standardized protocol for liberating N-glycans

Yoko Kita, Yoshiaki Miura, Jun-ichi Furukawa, Mika Nakano, Yasuro Shinohara, Masahiro Ohno, Akio Takimoto, and Shin-Ichiro Nishimura

Graduate School of Advanced Life Science, Hokkaido University, Sapporo, Hokkaido 001-0021

Corresponding Author: shin{at}glyco.sci.hokudai.ac.jp

Despite quantitative glycomics is premised on highly efficient and reproducible oligosaccharide liberation from human serum glycoproteins, it should be noted that there is no validated protocol of which deglycosylation efficiency is proven to be quantitative. Aiming to establish a standard procedure to release N-glycans present in whole human serum glycoproteins by peptide N-glycosidase F (PNGase F), we evaluated various conditions, where serum glycoproteins were denatured by either reducing agents, surfactants, protease treatment or the combination of these pretreatments prior to PNGase F digestion, in terms of their efficiencies of the liberation of major N-glycans. It was demonstrated that de-N-glycosylation efficiency could differ significantly depending on the condition employed, thus drawing attention for the accumulation and comparison of glycomic data. The maximum de-N-glycosylation was achieved only when serum was subjected to the reductive alkylation in the presence of 2-hydroxyl-3-sulfopropyl dodecanoate, a surfactant employed for solubilizing proteins, or other related analogues, followed by tryptic digestion prior to PNGase F treatment. The optimized de-N-glycosylation protocol permitted relative and absolute quantitation of as many as 23 major N-glycans present in serum glycoproteins for the first time. Furthermore, the process of PNGase F-catalyzed de-N-glycosylation of whole serum glycoproteins was characterized kinetically, which allowed accurate simulation of PNGase F-catalyzed de-N-glycosylation required in clinical glycomics using human serum samples. The present study reveals for the first time the absolute concentrations of major N-glycans existing in human serum whole glycoproteins by means of the optimized protocol for quantitative glycomics.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
L. Baudino, Y. Shinohara, F. Nimmerjahn, J.-I. Furukawa, M. Nakata, E. Martinez-Soria, F. Petry, J. V. Ravetch, S.-I. Nishimura, and S. Izui
Crucial Role of Aspartic Acid at Position 265 in the CH2 Domain for Murine IgG2a and IgG2b Fc-Associated Effector Functions
J. Immunol., November 1, 2008; 181(9): 6664 - 6669.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Baudino, F. Nimmerjahn, Y. Shinohara, J.-I. Furukawa, F. Petry, J. S. Verbeek, S.-I. Nishimura, J. V. Ravetch, and S. Izui
Impact of a Three Amino Acid Deletion in the CH2 Domain of Murine IgG1 on Fc-Associated Effector Functions
J. Immunol., September 15, 2008; 181(6): 4107 - 4112.
[Abstract] [Full Text] [PDF]

Home page
 GlycobiologyHome page
C. Cederfur, E. Salomonsson, J. Nilsson, A. Halim, C. T Oberg, G. Larson, U. J Nilsson, and H. Leffler
Different affinity of galectins for human serum glycoproteins: Galectin-3 binds many protease inhibitors and acute phase proteins
Glycobiology, May 1, 2008; 18(5): 384 - 394.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
Y. Miura, M. Hato, Y. Shinohara, H. Kuramoto, J.-i. Furukawa, M. Kurogochi, H. Shimaoka, M. Tada, K. Nakanishi, M. Ozaki, et al.
BlotGlycoABCTM, an Integrated Glycoblotting Technique for Rapid and Large Scale Clinical Glycomics
Mol. Cell. Proteomics, February 1, 2008; 7(2): 370 - 377.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.